MRK Biotech Wednesday, August 5, 2026 0.00 Neutral

Merck's KEYTRUDA Plus Enfortumab Vedotin Approved In Canada For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Patients

AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day